-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Victory Capital Management Inc. Raises Stake in Kura Oncology, Inc. (NASDAQ:KURA)
Victory Capital Management Inc. Raises Stake in Kura Oncology, Inc. (NASDAQ:KURA)
Victory Capital Management Inc. boosted its position in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 77.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,357,898 shares of the company's stock after purchasing an additional 591,580 shares during the period. Victory Capital Management Inc.'s holdings in Kura Oncology were worth $18,549,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new stake in Kura Oncology in the third quarter valued at approximately $39,000. Nisa Investment Advisors LLC boosted its position in Kura Oncology by 80.8% in the second quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company's stock valued at $60,000 after buying an additional 1,470 shares during the last quarter. Denali Advisors LLC boosted its position in Kura Oncology by 71.1% in the second quarter. Denali Advisors LLC now owns 6,500 shares of the company's stock valued at $119,000 after buying an additional 2,700 shares during the last quarter. Amalgamated Bank purchased a new stake in Kura Oncology in the first quarter valued at approximately $123,000. Finally, Principal Financial Group Inc. purchased a new stake in Kura Oncology in the second quarter valued at approximately $198,000.
Get Kura Oncology alerts:Kura Oncology Trading Up 3.6 %
Kura Oncology stock opened at $14.60 on Thursday. Kura Oncology, Inc. has a 12 month low of $10.41 and a 12 month high of $19.93. The stock's 50 day simple moving average is $13.63 and its two-hundred day simple moving average is $14.60. The firm has a market cap of $976.70 million, a PE ratio of -7.19 and a beta of 0.90.
Kura Oncology (NASDAQ:KURA – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.04. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.12 EPS for the current year.Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Kura Oncology in a research report on Wednesday, October 12th. They issued a "sell" rating on the stock. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.40.
Kura Oncology Company Profile
(Get Rating)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Featured Articles
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Get Rating).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
据Holdings Channel.com报道,胜利资本管理公司第三季度将其在库拉肿瘤公司(纳斯达克代码:Kura-Get Rating)的头寸提高了77.2%。该机构投资者持有该公司股票1,357,898股,在此期间又购买了591,580股。截至最近提交给美国证券交易委员会(Securities&Exchange Commission)的文件,Vicence Capital Management Inc.持有的Kura Oncology价值18,549,000美元。
其他大型投资者最近也买卖了该公司的股票。大西部人寿保险公司在第三季度购买了Kura Oncology的新股份,价值约3.9万美元。NISA Investment Advisors LLC在第二季度将其在Kura Oncology的头寸提高了80.8%。NISA Investment Advisors LLC现在持有该公司3290股股票,价值6万美元,在上个季度又购买了1470股。Denali Advisors LLC在第二季度将其在Kura Oncology的头寸提高了71.1%。Denali Advisors LLC现在持有该公司6,500股股票,价值11.9万美元,在上个季度又购买了2,700股。合并银行在第一季度购买了Kura Oncology的新股份,价值约12.3万美元。最后,信安金融集团公司在第二季度购买了Kura Oncology的新股份,价值约19.8万美元。
到达库拉肿瘤学警报:库拉肿瘤学交易上涨3.6%
库拉肿瘤学股票周四开盘报14.60美元。Kura Oncology,Inc.的12个月低点为10.41美元,12个月高位为19.93美元。该股的50日简单移动均线切入位为13.63美元,200日简单移动均线切入位为14.60美元。该公司市值为9.767亿美元,市盈率为-7.19,贝塔系数为0.90。
库拉肿瘤学(纳斯达克:库拉-GET评级)最近一次公布财报是在11月3日周四。该公司公布了本季度每股收益(0.53美元),比普遍预期的(0.57美元)高出0.04美元。平均而言,股票研究分析师预测Kura Oncology,Inc.本年度每股收益将达到2.12美元。分析师评级发生变化
另外,StockNews.com在10月12日星期三的一份研究报告中开始了对Kura肿瘤学的报道。他们对这只股票发布了“卖出”评级。一名股票研究分析师将该股评级为卖出,五名分析师将该公司股票的评级定为买入。根据MarketBeat,该公司的共识评级为“适度买入”,共识目标价为32.40美元。
库拉肿瘤学公司简介
(获取评级)
Kura Oncology,Inc.是一家临床阶段的生物制药公司,在美国开发治疗癌症的药物。该公司的流水线包括针对癌症的小分子候选产品。它的主要候选产品是齐托米尼,这是一种用于治疗包括急性髓细胞白血病和急性淋巴细胞白血病在内的遗传定义的急性白血病亚型的脑膜素-赖氨酸K特异性甲基转移酶2A蛋白质-蛋白质相互作用的小分子抑制剂;以及替普法尼,这是一种口服生物可用法尼基转移酶抑制剂,目前正处于治疗实体肿瘤和血液学适应症的第二阶段临床试验中。
专题文章
- 免费获取StockNews.com关于Kura肿瘤学的研究报告(Kura)
- AMD仍是市面上最好的半导体股票之一
- 两大股利大王:强生还是雅培?
- 网络安全类股已经见底了吗?
- 联合太平洋,诺福克南方进入购买区
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
想看看其他对冲基金持有库拉的股票吗?访问HoldingsChannel.com获取库拉肿瘤学公司(纳斯达克:库拉-获得评级)的最新13F备案和内幕交易。
接受《库拉肿瘤学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kura Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧